AbbVie’s HCV treatment receives first for shorter treatment cycle

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Jakkapan Sapmuangphan)
(Image: Getty/Jakkapan Sapmuangphan)

Related tags AbbVie Gilead Mavyret Hcv

US FDA granted expanded approval for Mavyret that will allow patients to be treated for the hepatitis C virus in eight weeks.

AbbVie’s Mavyret (glecaprevir/pibrentasvir) can now be administered to treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients, across all genotypes, in eight weeks.

It becomes the first once-daily treatment to have this duration, after previous standard treatments had needed 12 weeks or more.

AbbVie’s immediate rivals in the space, Gilead, possess treatment with such schedules, including Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) – though Gilead launched ‘early’ generic versions​ of these treatments to compete on pricing.

According to clinical trials undertaken by AbbVie, Mavyret was able to manage a sustained virologic response 12 weeks after treatment in 98% of patients, when they were treated with an eight-week dosing schedule.

“With more than 2.3 million people in the US still living with chronic HCV, access to shorter-term, eight-week treatment options can help us move closer to achieving the WHO’s goal of eliminating HCV by 2030,”​ said Robert Brown, professor of medicine at Weill Cornell Medical College, on the approval.

In AbbVie’s second-quarter financials​, the company posted that Mavyret had brought in $784m (€718m) in net revenue globally for the company.

AbbVie managed these sales despite an arrangement being made with the WHO for the distribution of Mavyret in low- and middle-income countries at a discount​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more